Clinical review report: Guselkumab (Tremfya) (Janssen Inc.)
The objective of this review was to perform a systematic review of the beneficial and harmful effects of guselkumab 100 mg administered as a subcutaneous (SC) injection for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, March 2018
|
| Edition: | Version: final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review was to perform a systematic review of the beneficial and harmful effects of guselkumab 100 mg administered as a subcutaneous (SC) injection for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy |
|---|---|
| Physical Description: | 1 PDF file (129 pages) illustrations |